Tango Q2 net loss $55.3M; vopimetostat combo 92% ORR, cash $1B

Tango Therapeutics, Inc.

2026-Q2 EPS reported -$0.68

Q2 net loss $55.3M ($0.37/share) vs $38.9M ($0.35/share) YoY; cash $1.0B as of June 30, 2026.
Vopimetostat + daraxonrasib showed 92% ORR and 90% 6-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer; advancing to Phase 3.
Data to be presented at ESMO 2026 (Oct 23-27, Madrid); plans to finalize Phase 3 design in 2H 2026.
Fatma Ocak appointed Chief Commercialization Officer effective Aug 17, 2026; Robert Azelby named Chairman Aug 6, 2026.
R&D expenses $37.2M (up from $32.8M), G&A $22.6M (up from $11.3M); collaboration revenue $0 vs $3.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.